Abstract

Research Article

Application of In vitro Reconstructed 3D Biomimetic Tumor Microenvironment Models in Cancer Research

Yinuo Ma, Zhiyuan Lu, Yili Sun and Jia Li

Published: 08 June, 2026 | Volume 10 - Issue 1 | Pages: 16-27

Cancer is a highly heterogeneous and dynamic disease whose progression, metastasis, therapeutic resistance, and immune escape are strongly regulated by the tumor microenvironment (TME). However, conventional two-dimensional (2D) cell culture systems and animal models often fail to recapitulate the structural organization, multicellular interactions, biochemical gradients, and mechanical properties of native tumors, thereby limiting the translational efficiency of preclinical cancer research and drug development. In recent years, in vitro three-dimensional (3D) biomimetic tumor models-including tumor spheroids, tumor organoids, and tumor-on-a-chip systems—have emerged as powerful platforms for reconstructing physiologically relevant tumor microenvironments and investigating complex tumor behaviors.
In this review, we systematically summarize the construction principles, biological characteristics, advantages, and limitations of major 3D biomimetic tumor models. We further discuss their recent applications in drug screening, precision medicine, tumor heterogeneity research, cancer stem cell investigation, metastasis, therapeutic resistance, and immunotherapy evaluation. Particular emphasis is placed on the comparative advantages of different 3D systems in modeling dynamic tumor–microenvironment interactions and supporting translational oncology research. Additionally, we will discuss the current problems of vascularisation, extracellular matrix biomimetics, experimental reproducibility, standardisation, and large-scale clinical translation. Finally, we present some new directions for future work, including three-dimensional bioprinting, multi-omics technology, artificial intelligence, and multi-organ-on-a-chip platforms, which may further improve the physiological relevance and predictive power of next-generation tumor models.
In short, this review has listed the current progress of 3D biomimetic tumour modelling and discussed some prospects for its use in mechanistic studies of cancer, drug discovery, etc.

Read Full Article HTML DOI: 10.29328/journal.acst.1001051 Cite this Article Read Full Article PDF

Keywords:

Tumor microenvironment; 3D biomimetic tumor models; Tumor spheroids; Tumor organoids; Tumor-on-a-chip; Precision oncology

References

  1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. Available from: https://doi.org/10.3322/caac.21834
  2. Mazzocchi A, Soker S, Skardal A. 3D bioprinting for high-throughput screening: drug screening, disease modeling, and precision medicine applications. Appl Phys Rev. 2019;6(1). Available from: https://doi.org/10.1063/1.5056188
  3. Yang Q, Li M, Yang X, et al. Flourishing tumor organoids: history, emerging technology, and application. Bioeng Transl Med. 2023;8(5):e10559.Available from: https://doi.org/10.1002/btm2.10559
  4. Zhou G, Lin X, Li H, et al. Assessment of drug treatment response using primary human colon cancer cell spheroids cultivated in a microfluidic mixer chip. Biosens Bioelectron. 2025;269:116944. Available from: https://doi.org/10.1016/j.bios.2024.116944
  5. Cordeiro S, Oliveira BB, Valente R, et al. Breaking the mold: 3D cell cultures reshaping the future of cancer research. Front Cell Dev Biol. 2024;12:1507388. Available from: https://doi.org/10.3389/fcell.2024.1507388
  6. Esposito A, Ferraresi A, Vallino L, et al. Three-dimensional in vitro cell cultures as a feasible and promising alternative to two-dimensional and animal models in cancer research. Int J Biol Sci. 2024;20(13):5293-311. Available from: https://doi.org/10.7150/ijbs.96469
  7. Fridman WH, Zitvogel L, Sautés-Fridman C, et al. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717-34.
  8. Sahai E, Astsaturov I, Cukierman E, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174-86. Available from: https://doi.org/10.1038/s41568-019-0238-1
  9. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-70. Available from: https://doi.org/10.1126/science.1203486
  10. Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662-80. Available from: https://doi.org/10.1038/s41568-020-0285-7
  11. Li W, Zhou Z, Zhou X, et al. 3D biomimetic models to reconstitute tumor microenvironment in vitro: spheroids, organoids, and tumor-on-a-chip. Adv Healthc Mater. 2023;12(18):e2202609. Available from: https://doi.org/10.1002/adhm.202202609
  12. Sutherland RM, McCredie JA, Inch WR. Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. J Natl Cancer Inst. 1971;46(1):113-20.
  13. Costa EC, Gaspar VM, Coutinho P, et al. Optimization of liquid overlay technique to formulate heterogenic 3D co-cultures models. Biotechnol Bioeng. 2014;111(8):1672-85. Available from: https://doi.org/10.1002/bit.25210
  14. Costa EC, Moreira AF, de Melo-Diogo D, et al. 3D tumor spheroids: an overview on the tools and techniques used for their analysis. Biotechnol Adv. 2016;34(8):1427-41. Available from: https://doi.org/10.1016/j.biotechadv.2016.11.002
  15. Han SJ, Kwon S, Kim KS. Challenges of applying multicellular tumor spheroids in preclinical phase. Cancer Cell Int. 2021;21(1):152.Available from: https://doi.org/10.1186/s12935-021-01853-8
  16. Qu J, Kalyani FS, Liu L, et al. Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy. Cancer Commun (Lond). 2021;41(12):1331-53. Available from: https://doi.org/10.1002/cac2.12224
  17. Friedrich J, Seidel C, Ebner R, et al. Spheroid-based drug screen: considerations and practical approach. Nat Protoc. 2009;4(3):309-24. Available from: https://doi.org/10.1038/nprot.2008.226
  18. Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459(7244):262-5. Available from: https://doi.org/10.1038/nature07935
  19. Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology. 2011;141(5):1762-79. Available from: https://doi.org/10.1053/j.gastro.2011.07.050
  20. Qu S, Xu R, Yi G, et al. Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine. Mol Biomed. 2024;5(1):6. Available from: https://doi.org/10.1186/s43556-023-00165-9
  21. Chew CA, Wun CM, Lee YF, et al. Functional precision in pancreatic cancer: redefining biomarkers with patient-derived organoids. Int J Mol Sci. 2025;26(18). Available from: https://doi.org/10.3390/ijms26189083
  22. Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172(1-2):373-86.e10. Available from: https://doi.org/10.1016/j.cell.2017.11.010
  23. Kim M, Mun H, Sung CO, et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun. 2019;10(1):3991. Available from: https://doi.org/10.1038/s41467-019-11867-6
  24. Mullenders J, de Jongh E, Brousali A, et al. Mouse and human urothelial cancer organoids: a tool for bladder cancer research. Proc Natl Acad Sci U S A. 2019;116(10):4567-74. Available from: https://doi.org/10.1073/pnas.1803595116
  25. Kopper O, de Witte CJ, Lõhmussaar K, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019;25(5):838-49. Available from: https://doi.org/10.1038/s41591-019-0422-6
  26. Shi R, Radulovich N, Ng C, et al. Organoid cultures as preclinical models of non-small cell lung cancer. Clin Cancer Res. 2020;26(5):1162-74. Available from: https://doi.org/10.1158/1078-0432.ccr-19-1376
  27. Wensink E, Bond M, Kucukkose E, et al. A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research. Cancer Treat Rev. 2021;95:102174. Available from: https://doi.org/10.1016/j.ctrv.2021.102174
  28. Xu H, Jiao Y, Qin S, et al. Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine. Exp Hematol Oncol. 2018;7:30. Available from: https://doi.org/10.1186/s40164-018-0122-9
  29. Di Paola FJ, Calafato G, Piccaluga PP, et al. Patient-derived organoid biobanks for translational research and precision medicine: challenges and future perspectives. J Pers Med. 2025;15(8). Available from: https://doi.org/10.3390/jpm15080394
  30. Xu J, Feng Q, Xia Y, et al. Organoids glimpse: the nexus for diverse tumor heterogeneity. Front Cell Dev Biol. 2026;14:1817560. Available from: https://doi.org/10.3389/fcell.2026.1817560
  31. Bai M, Liu M, Wang S, et al. Organoids in cancer therapy: translational applications and clinical promise. Mol Cancer. 2026.
  32. Huh D, Matthews BD, Mammoto A, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662-8. Available from: https://doi.org/10.1126/science.1188302
  33. Bhise NS, Manoharan V, Massa S, et al. A liver-on-a-chip platform with bioprinted hepatic spheroids. Biofabrication. 2016;8(1):014101. Available from: https://doi.org/10.1088/1758-5090/8/1/014101
  34. Zhang YS, Arneri A, Bersini S, et al. Bioprinting 3D microfibrous scaffolds for engineering endothelialized myocardium and heart-on-a-chip. Biomaterials. 2016;110:45-59. Available from: https://doi.org/10.1016/j.biomaterials.2016.09.003
  35. Ma LD, Wang YT, Wang JR, et al. Design and fabrication of a liver-on-a-chip platform for convenient, highly efficient, and safe in situ perfusion culture of 3D hepatic spheroids. Lab Chip. 2018;18(17):2547-62. Available from: https://doi.org/10.1039/c8lc00333e
  36. Ashammakhi N, Wesseling-Perry K, Hasan A, et al. Kidney-on-a-chip: untapped opportunities. Kidney Int. 2018;94(6):1073-86. Available from: https://doi.org/10.1016/j.kint.2018.06.034
  37. Kamei KI, Yoshioka M, Terada S, et al. Three-dimensional cultured liver-on-a-chip with mature hepatocyte-like cells derived from human pluripotent stem cells. Biomed Microdevices. 2019;21(3):73. Available from: https://doi.org/10.1007/s10544-019-0423-8
  38. Herland A, Maoz BM, Das D, et al. Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips. Nat Biomed Eng. 2020;4(4):421-36. Available from: https://doi.org/10.1038/s41551-019-0498-9
  39. Jeon MS, Choi YY, Mo SJ, et al. Contributions of the microbiome to intestinal inflammation in a gut-on-a-chip. Nano Converg. 2022;9(1):8. Available from: https://doi.org/10.1186/s40580-022-00299-6
  40. Kohl Y, Biehl M, Spring S, et al. Microfluidic in vitro platform for (nano)safety and (nano)drug efficiency screening. Small. 2021;17(15):e2006012. Available from: https://doi.org/10.1002/smll.202006012
  41. Lee J, Mehrotra S, Zare-Eelanjekh E, et al. A heart-breast cancer-on-a-chip platform for disease modeling and monitoring of cardiotoxicity induced by cancer chemotherapy. Small. 2021;17(15):e2004258. Available from: https://doi.org/10.1002/smll.202004258
  42. Baek S, Yu SE, Deng YH, et al. Quenching epigenetic drug resistance using antihypoxic microparticles in glioblastoma patient-derived chips. Adv Healthc Mater. 2022;11(8):e2102226. Available from: https://doi.org/10.1002/adhm.202102226
  43. Lim J, Ching H, Yoon JK, et al. Microvascularized tumor organoids-on-chips: advancing preclinical drug screening with pathophysiological relevance. Nano Converg. 2021;8(1):12. Available from: https://doi.org/10.1186/s40580-021-00261-y
  44. Papamichail L, Koch LS, Veerman D, et al. Organoids-on-a-chip: microfluidic technology enables culture of organoids with enhanced tissue function and potential for disease modeling. Front Bioeng Biotechnol. 2025;13:1515340. Available from: https://doi.org/10.3389/fbioe.2025.1515340
  45. Azim MMN, Bhajan SK, Park JH, et al. Stem cell-derived organoids for cancer therapy: precision medicine and drug selection. Int J Mol Sci. 2026;27(7).
  46. Gaebler D, Hachey SJ, Hughes CCW. Improving tumor microenvironment assessment in chip systems through next-generation technology integration. Front Bioeng Biotechnol. 2024;12:1462293. Available from: https://doi.org/10.3389/fbioe.2024.1462293
  47. Liu L, Wang H, Chen R, et al. Cancer-on-a-chip for precision cancer medicine. Lab Chip. 2025;25(14):3314-47. Available from: https://doi.org/10.1039/d4lc01043d
  48. Kim H, Cho SW, Kim HN. Vascularized tumor-on-a-chip model as a platform for studying tumor-microenvironment-drug interaction. Macromol Biosci. 2025;25(10):e00240. Available from: https://doi.org/10.1002/mabi.202500240
  49. Lonkwic KM, Zajdel R, Kaczka K. Unlocking the potential of spheroids in personalized medicine: a systematic review of seeding methodologies. Int J Mol Sci. 2025;26(13). Available from: https://doi.org/10.3390/ijms26136478
  50. Tan X, Huang B, Yang X, et al. Construction and application of pancreatic exocrine organoid and spheroid for drug screening and precision medicine. Front Cell Dev Biol. 2025;13:1746622. Available from: https://doi.org/10.3389/fcell.2025.1746622
  51. Fatehullah A, Tan SH, Barker N. Organoids as an in vitro model of human development and disease. Nat Cell Biol. Available from: 2016;18(3):246-54. https://doi.org/10.1038/ncb3312
  52. Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18(7):407-18. Available from: https://doi.org/10.1038/s41568-018-0007-6
  53. Fan X, Hou K, Liu G, et al. Strategies to overcome the limitations of current organoid technology—engineered organoids. J Tissue Eng. 2025;16:20417314251319475. Available from: https://doi.org/10.1177/20417314251319475
  54. Lipreri MV, Totaro MT, Baldini N, et al. From spheroids to tumor-on-a-chip for cancer modeling and therapeutic testing. Micromachines. 2025;16(12). Available from: https://doi.org/10.3390/mi16121343
  55. Wang LX, Liu SL, Wu N. Application and development of organ-on-a-chip technology in cancer therapy. Front Oncol. 2025;15:1643230. https://doi.org/10.3389/fonc.2025.1643230
  56. Momoli C, Costa B, Lenti L, et al. The evolution of anticancer 3D in vitro models: the potential role of machine learning and AI in the next generation of animal-free experiments. Cancers. 2025;17(4). Available from: https://doi.org/10.3390/cancers17040700
  57. Chen J, Yang H. Convergent bioprinting and microfluidics: toward next-generation biomimetic tumor models. Hepatobiliary Surg Nutr. 2026;15(1):18. Available from: https://doi.org/10.21037/hbsn-2026-1-0021
  58. Manduca N, Maccafeo E, De Maria R, et al. 3D cancer models: one step closer to in vitro human studies. Front Immunol. 2023;14:1175503. Available from: https://doi.org/10.3389/fimmu.2023.1175503
  59. Sharma K, Dey S, Karmakar R, et al. A comprehensive review of 3D cancer models for drug screening and translational research. Cancer Innov. 2024;3(1):e102. Available from: https://doi.org/10.1002/cai2.102
  60. Guan X, Huang S. Advances in the application of 3D tumor models in precision oncology and drug screening. Front Bioeng Biotechnol. 2022;10:1021966. Available from: https://doi.org/10.3389/fbioe.2022.1021966
  61. Bagheri M, Tabatabae Far MA, Mirzaei H, et al. Evaluation of antitumor effects of aspirin and LGK974 drugs on cellular signaling pathways, cell cycle and apoptosis in colorectal cancer cell lines compared to oxaliplatin drug. Fundam Clin Pharmacol. 2020;34(1):51-64. Available from: https://doi.org/10.1111/fcp.12492
  62. Mao Y, Wang W, Yang J, et al. Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids. Protein Cell. 2024;15(4):285-304. Available from: https://doi.org/10.1093/procel/pwad038
  63. Chen P, Zhang X, Ding R, et al. Patient-derived organoids can guide personalized therapies for patients with advanced breast cancer. Adv Sci. 2021;8(22):e2101176. Available from: https://doi.org/10.1002/advs.202101176
  64. Wang HM, Zhang CY, Peng KC, et al. Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: a real-world study. Cell Rep Med. 2023;4(2):100911. Available from: https://doi.org/10.1016/j.xcrm.2022.100911
  65. Yan HHN, Siu HC, Law S, et al. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell. 2018;23(6):882-97.e11. Available from: https://doi.org/10.1016/j.stem.2018.09.016
  66. Zhang A, Miao K, Sun H, et al. Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. Int J Biol Sci. 2022;18(7):3019-33. Available from: https://doi.org/10.7150/ijbs.72534
  67. Lamichhane A, Tavana H. Three-dimensional tumor models to study cancer stemness-mediated drug resistance. Cell Mol Bioeng. 2024;17(2):107-19. Available from: https://doi.org/10.1007/s12195-024-00798-y
  68. Coppo R, Inoue M. Patient-derived tumor organoids to model cancer cell plasticity and overcome therapeutic resistance. Cells. 2025;14(18). Available from: https://doi.org/10.3390/cells14181464
  69. Liu Y, Dai Y, Wang L. Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications. Cancer Cell. 2026;44(1):24-49. Available from: https://doi.org/10.1016/j.ccell.2025.12.009
  70. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. Available from: https://doi.org/10.1158/2159-8290.cd-21-1059
  71. Kim HY, Bae SJ, Choi JW, et al. Cholesterol synthesis is important for breast cancer cell tumor sphere formation and invasion. Biomedicines. 2022;10(8). Available from: https://doi.org/10.3390/biomedicines10081908
  72. Zhang X, Bai JJ, Fan SC, et al. Dissecting exosomal-tumoral-vascular interactions of single tumor cells and clusters using a tumoral-transendothelial migration chip. ACS Nano. 2025;19(26):23680-92.
  73. Jo H, Lee S, Kim MH, et al. Recapitulating glioma stem cell niches using 3D spheroid models for glioblastoma research. Biosensors. 2024;14(11). Available from: https://doi.org/10.3390/bios14110539
  74. Pamarthy S, Sabaaawy HE. Patient-derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine. Mol Cancer. 2021;20(1):125. Available from: https://doi.org/10.1186/s12943-021-01426-3
  75. Fitzgerald AA, Li E, Weiner LM. 3D culture systems for exploring cancer immunology. Cancers. 2020;13(1). Available from: https://doi.org/10.3390/cancers13010056
  76. Si Q, Tao S, Wu J, et al. Tumor organoids in immunotherapy: from disease modeling to translational research. J Immunother Cancer. 2025;13(7). Available from: https://doi.org/10.1136/jitc-2025-011733
  77. Wang Q, Yuan F, Zuo X, et al. Breakthroughs and challenges of organoid models for assessing cancer immunotherapy: a cutting-edge tool for advancing personalised treatments. Cell Death Discov. 2025;11(1):222. Available from: https://doi.org/10.1038/s41420-025-02505-w
  78. Chen X, Tan D, Liu S, et al. Applying microfluidic technology to interpret the tumor immune microenvironment and cancer immunotherapy. Cancer Biol Med. 2026;23(2):169-85. Available from: https://doi.org/10.20892/j.issn.2095-3941.2025.0541
  79. Poljak I, Chiappini C, Adriani G. Engineering perfusion to meet tumor biology: are vascularized tumor-on-a-chip models ready to drive therapy innovation? Lab Chip. 2026;26(5):1162-90.
  80. Menzani B, De Gea P, Gidrol X, et al. Vascularizing organoids-on-chip for perfused and personalized models. Lab Chip. 2026;26(6):1798-819. Available from: https://doi.org/10.1039/d5lc00890e
  81. Jose A, Kulkarni P, Thilakan J, et al. Integration of pan-omics technologies and three-dimensional in vitro tumor models: an approach toward drug discovery and precision medicine. Mol Cancer. 2024;23(1):50.Available from: https://doi.org/10.1186/s12943-023-01916-6
  82. Cao X, Xia C, Li C, et al. Organ-on-a-chip technology and global multi-omics: current applications and future directions. MedComm. 2026;7(2):e70603. Available from: https://doi.org/10.1002/mco2.70603
  83. Wolff L, Hendrix S. Rethinking Matrigel: the complex journey to matrix alternatives in organoid culture. Adv Sci. 2025;12(47):e08734. Available from: https://doi.org/10.1002/advs.202508734
  84. Du L, Yang H. Spatial omics in 3D culture model systems: decoding cellular positioning mechanisms and microenvironmental dynamics. J Transl Med. 2025;23(1):1356. Available from: https://doi.org/10.1186/s12967-025-07390-6
  85. Piotrowska U, Tsoi J, Singh P, et al. 3D bioprinting and artificial intelligence for tumor microenvironment modeling: a scoping review of models, methods, and integration pathways. Mol Pharm. 2025;22(10):5801-23. Available from: https://doi.org/10.1021/acs.molpharmaceut.5c01062

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?